Volume 27, Issue 2 (January 2017)

An update on bisphosphonates and trends in drug therapy for osteoporosis. Drug selection and treatment goal in osteoporosis therapy. Yamauchi Mika 1 , Sugimoto Toshitsugu 2 1Internal Medicine 1, Shimane University Faculty of Medicine, Japan. 2Internal Medicine 1, Shimane University Faculty of Medicine, Japan. pp.189-196
Published Date 2017/1/28
DOI https://doi.org/10.20837/4201702015
  • Abstract
  • Look Inside
  • Reference

 The goal of treatment for osteoporosis is to reduce the risk of fracture. Achieving effective reductions in the risk of fracture requires evidence-based drug selection and careful consideration of patient background, including concomitant diseases and drug adherence. Selective estrogen receptor modulators(SERM)and active vitamin D3 such as eldecalcitol are well indicated in early menopausal women with no history of fragility fractures. Moreover, elderly individuals with a history of fragility fractures are at high risk of vertebral and hip fractures, so bisphosphonates, denosumab and teriparatide are well indicated in these patients. Although no well-established goal has been devised for the treatment of osteoporosis in Japan, the strategy of goal-directed treatment of osteoporosis has been reported in the United States.


27巻2号 (2017年1月)
電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社